Clinical Trial

Testing Experimental Medication in Healthy Subjects

Study Description

FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects

The study will comprise primarily a single-ascending dose (SAD) escalation component.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - GFB-887

IMP

Drug - Placebo

Matching

Additional Information

Official Study Title

A First-In-Human, Phase 1, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GFB-887, a TRPC5 Channel Inhibitor, in Healthy Subjects

Clinical Trial ID

NCT03970122

ParticipAid ID

bW60Ea